Merck & Co., Inc: Depressive Disorder, Major trials
The registry lists 10 Depressive Disorder, Major studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 1 have results posted.
Phase 2 1Phase 3 9(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)TerminatedNCT01554176Phase 2Results posted
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)CompletedNCT00048607Phase 3
- Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)CompletedNCT00048594Phase 3
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)CompletedNCT00042029Phase 3
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)CompletedNCT00035295Phase 3
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)CompletedNCT00035282Phase 3
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)CompletedNCT00035048Phase 3
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)CompletedNCT00035009Phase 3
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)CompletedNCT00034983Phase 3
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)CompletedNCT00034944Phase 3